|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
2,630,000,000 |
Market
Cap: |
406.70(B) |
Last
Volume: |
6,512,369 |
Avg
Vol: |
8,301,717 |
52
Week Range: |
$144.45 - $174.48 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
DOW JONES COMPOSITE |
|
DOW JONES INDUSTRIAL AVERAGE |
|
NYSE COMPOSITE |
|
S&P 100 |
|
S&P 500 |
|
MAJOR MARKET |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 21 |
Guru Rank Value : 20.3 |
Guru Occurances : 6 |
|
|
|
|
|
|
|
Company Profile Johnson & Johnson is a holding company. Through its subsidiaries, Co. is engaged in the research and development, manufacture and sale of products in the health care field. Co. has three business segments: Consumer Health, which includes products focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women's health and wound care markets; Pharmaceutical, which is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension; and Medical Devices, which includes products used in the Interventional Solutions, Orthopaedics, Surgery, and Vision fields.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
8,891 |
68,288 |
115,451 |
522,170 |
Total Sell Value |
$1,441,765 |
$10,723,734 |
$18,652,688 |
$88,845,171 |
Total People Sold |
1 |
2 |
5 |
10 |
Total Sell Transactions |
1 |
2 |
5 |
24 |
End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kapusta Ronald A |
Controller, CAO |
|
2018-09-07 |
4 |
S |
$137.18 |
$1,083,607 |
D/D |
(7,899) |
25,725 |
|
- |
|
Mcevoy Ashley |
EVP, WW Chair, Medical Devices |
|
2018-08-27 |
4 |
D |
$134.92 |
$19,159 |
I/I |
(142) |
2,215 |
|
- |
|
Sneed Michael E |
EVP, Global Corp Aff & COO |
|
2018-08-27 |
4 |
S |
$134.80 |
$3,909,084 |
D/D |
(29,000) |
30,124 |
|
- |
|
Sneed Michael E |
EVP, Global Corp Aff & COO |
|
2018-08-27 |
4 |
OE |
$58.33 |
$1,691,570 |
D/D |
29,000 |
59,124 |
|
- |
|
Wengel Kathryn E |
EVP, Chief GSC OfficerOfficer |
|
2018-07-02 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
42,357 |
|
- |
|
Ullmann Michael H |
Exec VP, General Counsel |
|
2018-04-05 |
4 |
GD |
$0.00 |
$0 |
D/D |
385 |
122,985 |
|
- |
|
Ullmann Michael H |
Exec VP, General Counsel |
|
2018-03-09 |
4 |
GD |
$0.00 |
$0 |
D/D |
380 |
123,370 |
|
- |
|
Stoffels Paulus |
Exec VP, Chief Scientific Off |
|
2018-02-15 |
4 |
S |
$129.86 |
$20,172,401 |
D/D |
(155,342) |
202,564 |
|
- |
|
Stoffels Paulus |
Exec VP, Chief Scientific Off |
|
2018-02-15 |
4 |
OE |
$90.44 |
$14,049,130 |
D/D |
155,342 |
357,906 |
|
- |
|
Stoffels Paulus |
Exec VP, Chief Scientific Off |
|
2018-02-12 |
4 |
D |
$129.51 |
$2,533,734 |
D/D |
(19,564) |
202,564 |
|
- |
|
Stoffels Paulus |
Exec VP, Chief Scientific Off |
|
2018-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
11,927 |
222,128 |
|
- |
|
Stoffels Paulus |
Exec VP, Chief Scientific Off |
|
2018-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
33,130 |
210,201 |
|
- |
|
Gorsky Alex |
Chairman, CEO |
|
2018-02-12 |
4 |
D |
$129.51 |
$6,341,069 |
D/D |
(48,962) |
336,559 |
|
- |
|
Gorsky Alex |
Chairman, CEO |
|
2018-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
29,849 |
385,521 |
|
- |
|
Gorsky Alex |
Chairman, CEO |
|
2018-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
82,913 |
355,672 |
|
- |
|
Caruso Dominic J |
Exec VP, Finance; CFO |
|
2018-02-12 |
4 |
D |
$129.51 |
$2,027,091 |
D/D |
(15,652) |
171,659 |
|
- |
|
Caruso Dominic J |
Exec VP, Finance; CFO |
|
2018-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
9,542 |
187,311 |
|
- |
|
Caruso Dominic J |
Exec VP, Finance; CFO |
|
2018-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
26,504 |
177,769 |
|
- |
|
Fasolo Peter |
Exec VP, Chief HR Officer |
|
2018-02-12 |
4 |
D |
$129.51 |
$1,226,589 |
D/D |
(9,471) |
78,327 |
|
- |
|
Fasolo Peter |
Exec VP, Chief HR Officer |
|
2018-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
5,247 |
87,798 |
|
- |
|
Fasolo Peter |
Exec VP, Chief HR Officer |
|
2018-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,574 |
82,551 |
|
- |
|
Duato Joaquin |
Exec VP, WW Chair, Pharma |
|
2018-02-12 |
4 |
D |
$129.51 |
$1,876,082 |
D/D |
(14,486) |
93,555 |
|
- |
|
Duato Joaquin |
Exec VP, WW Chair, Pharma |
|
2018-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
8,831 |
108,041 |
|
- |
|
Duato Joaquin |
Exec VP, WW Chair, Pharma |
|
2018-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,530 |
99,210 |
|
- |
|
Peterson Sandra E |
Exec VP, Group WW Chairman |
|
2018-02-12 |
4 |
D |
$129.51 |
$2,696,269 |
D/D |
(20,819) |
83,349 |
|
- |
|
1526 Records found
|
|
Page 17 of 62 |
|
|